Sherwin JE - Search Results

1

Krantz DA, Hallahan TW, Sherwin JE. Krantz DA, et al. Among authors: sherwin je. Clin Lab Med. 2010 Sep;30(3):721-5. doi: 10.1016/j.cll.2010.04.010. Epub 2010 Jun 15. Clin Lab Med. 2010. PMID: 20638584 Review.

2

First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay.

Krantz D, Hallahan T, Ravens R, He K, Cuckle H, Sherwin J, Carmichael J. Krantz D, et al. Prenat Diagn. 2011 Sep;31(9):869-74. doi: 10.1002/pd.2792. Epub 2011 Jun 21. Prenat Diagn. 2011. PMID: 21692092

3

First-trimester screening in triplets.

Krantz DA, Hallahan TW, He K, Sherwin JE, Evans MI. Krantz DA, et al. Among authors: sherwin je. Am J Obstet Gynecol. 2011 Oct;205(4):364.e1-5. doi: 10.1016/j.ajog.2011.06.107. Epub 2011 Aug 27. Am J Obstet Gynecol. 2011. PMID: 22083057

4

Undermeasurement of nuchal translucencies: implications for screening.

Evans MI, Krantz DA, Hallahan TW, Sherwin JE. Evans MI, et al. Among authors: sherwin je. Obstet Gynecol. 2010 Oct;116(4):815-818. doi: 10.1097/AOG.0b013e3181f23ae3. Obstet Gynecol. 2010. PMID: 20859143

5

Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance.

Evans MI, Krantz DA, Hallahan TW, Sherwin J. Evans MI, et al. Ultrasound Obstet Gynecol. 2012 Feb;39(2):181-4. doi: 10.1002/uog.9023. Epub 2011 Nov 1. Ultrasound Obstet Gynecol. 2012. PMID: 21484907 Free article.

6

Quality of nuchal translucency measurements correlates with broader aspects of program rigor and culture of excellence.

Evans MI, Krantz DA, Hallahan T, Sherwin J, Britt DW. Evans MI, et al. Fetal Diagn Ther. 2013;33(4):230-4. doi: 10.1159/000346418. Epub 2013 Mar 14. Fetal Diagn Ther. 2013. PMID: 23548741

7

A Tournaisian (earliest Carboniferous) conglomerate-preserved non-marine faunal assemblage and its environmental and sedimentological context.

Clack JA, Bennett CE, Davies SJ, Scott AC, Sherwin JE, Smithson TR. Clack JA, et al. Among authors: sherwin je. PeerJ. 2019 Jan 3;6:e5972. doi: 10.7717/peerj.5972. eCollection 2019. PeerJ. 2019. PMID: 30627480 Free PMC article.

8

Use of the phenylalanine:tyrosine ratio to test newborns for phenylketonuria in a large public health screening programme.

Eastman JW, Sherwin JE, Wong R, Liao CL, Currier RJ, Lorey F, Cunningham G. Eastman JW, et al. Among authors: sherwin je. J Med Screen. 2000;7(3):131-5. doi: 10.1136/jms.7.3.131. J Med Screen. 2000. PMID: 11126161

9

Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours.

Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC. Chace DH, et al. Among authors: sherwin je. Clin Chem. 1998 Dec;44(12):2405-9. Clin Chem. 1998. PMID: 9836704

10

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

Kahn JO, Allan JD, Hodges TL, Kaplan LD, Arri CJ, Fitch HF, Izu AE, Mordenti J, Sherwin JE, Groopman JE, et al. Kahn JO, et al. Among authors: sherwin je. Ann Intern Med. 1990 Feb 15;112(4):254-61. doi: 10.7326/0003-4819-112-4-. Ann Intern Med. 1990. PMID: 2297204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page